
Key Points
- 01Bristol Myers will unify scientific and clinical teams into one R&D unit
- 02Cristian Massacesi to lead the end-to-end R&D organization from Jan. 1, 2027
- 03Chief Research Officer Robert Plenge to advise through March 2027 before departing
- 04The restructuring aims to speed decisions and strengthen collaboration across the pipeline
Bristol Myers overhauls R&D into unified organization
Bristol Myers Squibb (BMY) is consolidating its scientific and clinical operations into a single, end-to-end research and development organization effective January 1, 2027. The restructuring will merge the company’s research and development functions, bringing together scientific and clinical teams under one umbrella to manage drug development from discovery through late-stage development.
The unified organization will be led by Cristian Massacesi, who currently serves as executive vice president and chief medical officer. Massacesi will assume the additional role of Head of R&D while maintaining his existing responsibilities, placing overall R&D leadership under a single executive.
Leadership transition and role of Robert Plenge
As part of the transition, current Chief Research Officer Robert Plenge will shift into an advisory role through March 2027. After supporting the handover to the new structure, Plenge is scheduled to leave the company following this advisory period.
Plenge has described his tenure at Bristol Myers Squibb (BMY) as an opportunity to work with exceptional scientists and noted that he and Massacesi jointly developed the new R&D structure. He expressed confidence that the unified organization is the right path forward for the company and for patients.
Strategic goals of the new R&D structure
Bristol Myers Squibb states that combining research and development into one organization is intended to strengthen collaboration from discovery through development. By unifying scientific and clinical expertise, the company aims to advance its pipeline with greater speed and sharper focus, while maintaining a shared commitment to delivering medicines for patients.
Chief Executive Officer and board chair Christopher Boerner said that bringing research and development together is an important step in positioning the company for long-term growth. He highlighted that traditional boundaries between research and development are increasingly collapsing and that the new structure is designed to connect scientific and clinical expertise, accelerate decision making and enhance portfolio execution.
Operational implications and remaining unknowns
Under the new structure, Bristol Myers Squibb plans to operate R&D as one integrated organization, aligning oversight of early discovery and clinical development activities. Company statements emphasize faster decision making and stronger cross-functional collaboration as expected outcomes of the reorganization.
The company has not provided details on the size of the teams involved or on specific reporting lines within the unified R&D unit. While executives and senior leaders have outlined the strategic intent of the change, operational specifics beyond the leadership appointments and transition timeline remain undisclosed.
Key Takeaways
- 01Bristol Myers Squibb (BMY) is shifting to a single, end-to-end R&D organization led by its current chief medical officer, consolidating accountability for drug discovery and development.
- 02The transition includes a defined leadership handover, with Chief Research Officer Robert Plenge advising through March 2027 before his departure.
- 03Management frames the restructuring as a way to tighten the link between scientific and clinical work, aiming for faster decisions and stronger execution across the pipeline despite limited disclosed operational detail.
References
- https://www.1049thewolf.com/2026/11/12/bristol-myers-to-merge-scientific-clinical-teams-under-new-rd-structure/
- https://www.investing.com/news/company-news/bristol-myers-squibb-unifies-rd-under-new-leadership-93CH-5021260
- https://www.biospace.com/press-releases/bristol-myers-squibb-announces-evolution-of-research-development-organization-november-12-2026
- https://nl.investing.com/news/company-news/bristol-myers-squibb-verenigt-rd-onder-nieuwe-leiding-93CH-972628